Establishment of plasmacytoid dendritic cell-based immune therapy against viral hepatitis and hepatocellular carcinoma

基于浆细胞样树突状细胞的病毒性肝炎和肝细胞癌免疫疗法的建立

基本信息

  • 批准号:
    16590592
  • 负责人:
  • 金额:
    $ 2.56万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2004
  • 资助国家:
    日本
  • 起止时间:
    2004 至 2006
  • 项目状态:
    已结题

项目摘要

The aim of the research project was to clarify the roles of dendritic cells (DC), including myeloid DC (MDC) or plasmacytoid DC (PDC), in the pathogenesis of hepatitis C virus-induced chronic hepatitis and hepatocellular carcinoma (HCC). In addition, we aimed to clarify the roles of DC system in the efficacy of IFN-a-based anti-HCV treatment.The frequencies of blood MDC and PDC were decreased in HCV-infected patients compared to healthy donors. The abilities of both DC subsets, such as cytokine production and stimulation of T cells and NK cells, were significantly impaired as well. With regard to the capacity of Th polarization, MDC from the patients were less able to induce Thl response. However, PDC from the patients induced more IL-10-producing regulatory T cells, contributing to the alleviation of liver inflammation:In chronic hepatitis C patients who underwent 48-week peg-IFNα and ribavirin therapy, we examined the frequencies of DC subsets and DC function throughout the therapy. … More In patients who attained sustained virological response (SVR), PDC frequency during the course was higher and DC ability at the end of therapy was better than those in patients who showed transient response (TR). These results demonstrate that maintenance of PDC frequency and DC function are involved in the IFN-mediated HCV eradication.Dendritic cells utilize toll-like receptors (TLR), RIG-I and MDA-5 to sense virus and induce innate as well as adaptive immune responses. The expressions of TLR2,TLR4 and RIG-I in patients MDC were significantly higher than those in donor MDC. In contrast, TLR3 and MDA-5 expressions were comparable between them. When stimulated with specific agonists against TLR2,TLR3,TLR4 and RIG-I, MDC from the patients induced significantly less IFN-β and TNF-α, indicating signal transduction in the downstream of TLR and RIG-I was impaired in MDC from the patients. From the comprehensive RT-PCR analyses, the levels of TRIF and TRAF6 expression were significantly decreased in patient MDC, suggesting the possible role in HCV-induced signal interference.In summary, DC system is a critical target of anti-HCV immune therapy: enhancing function of MDC leads to HCV eradication and that of PDC for retardation of disease progression, respectively. Less
研究项目的目的是阐明树突状细胞(DC)的作用,包括髓样DC(MDC)或浆细胞类动物DC(PDC),在丙型肝炎诱导的慢性肝炎和肝细胞癌(HCC)的发病机理中。此外,我们旨在阐明直流系统在基于IFN-A的抗HCV治疗效率中的作用。与健康供体相比,HCV感染患者的血液MDC和PDC的频率得到了提高。 DC亚群的能力,例如细胞因子的产生和T细胞和NK细胞的刺激,也受到显着损害。关于TH极化的能力,来自患者的MDC降低了THL反应。然而,来自患者的PDC诱导了更多产生的IL-10调节性T细胞,这有助于减轻肝脏注射:在慢性丙型肝炎患者中,他们接受了48周的PEG-IFNα和Ribavirin疗法,我们检查了整个治疗过程中DC子集和DC功能的频率。 …在接受病毒学反应(SVR)的患者中,更多的患者在治疗过程中的PDC频率较高,而治疗结束时的直流能力比表现出短暂反应(TR)的患者中的DC能力更好。这些结果表明,IFN介导的HCV消除涉及PDC频率和直流功能的维持。树突状细胞利用类似Toll样受体(TLR),RIG-I和MDA-5来感知病毒并诱导先天性以及适应性免疫蛋白。 MDC患者中TLR2,TLR4和RIG-I的表达明显高于供体MDC。相反,它们之间的TLR3和MDA-5表达式是可比的。当用特异性激动剂针对TLR2,TLR3,TLR4和RIG-I,来自患者的MDC刺激时,诱导的IFN-β和TNF-α明显较小,表明患者在MDC中损害了TLR和RIG-I下游的信号转导。从全面的RT-PCR分析中,患者MDC的TRIF和TRAF6表达水平显着降低,这表明在HCV诱导的信号干扰中可能作用。总而言之,DC系统是抗HCV免疫疗法的关键目标:MDC的功能提高了MDC的功能,导致HCV消除PDC的PDC和PDC的疾病进展。较少的

项目成果

期刊论文数量(108)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection.
  • DOI:
    10.1016/j.hepres.2005.12.010
  • 发表时间:
    2006-03
  • 期刊:
  • 影响因子:
    0
  • 作者:
    T. Yakushijin;T. Kanto;M. Inoue;T. Oze;M. Miyazaki;Ichiyo Itose;H. Miyatake;Mitsuru Sakakibara;N. Kuzushita;N. Hiramatsu;T. Takehara;A. Kasahara;N. Hayashi
  • 通讯作者:
    T. Yakushijin;T. Kanto;M. Inoue;T. Oze;M. Miyazaki;Ichiyo Itose;H. Miyatake;Mitsuru Sakakibara;N. Kuzushita;N. Hiramatsu;T. Takehara;A. Kasahara;N. Hayashi
Quick generation of fully mature dendritic cells from monocytes with OK432, low-dose prostanoid, and interferon-alpha as potent immune enhancers.
使用 OK432、低剂量前列腺素和干扰素-α 作为有效的免疫增强剂,从单核细胞快速生成完全成熟的树突状细胞。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sakakibara;M.;Kanto;T.et al.
  • 通讯作者:
    T.et al.
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
慢性丙型肝炎患者在干扰素加利巴韦林联合治疗期间,血红蛋白的早期下降与利巴韦林诱导的溶血性贫血的进展相关。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Uno S;et al.;Wada A;Ujiie H;Matsumoto H;Fukui K;Oze T
  • 通讯作者:
    Oze T
Impaired ability of interferon-alpha-primed dendritic cells to stimulate Thl-type CD4 T cell response in chronic hepatitis C virus infection.
在慢性丙型肝炎病毒感染中,干扰素α引发的树突状细胞刺激Thl型CD4 T细胞反应的能力受损。
Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-a2b and ribavirin therapy for chronic hepatitis C patients.
慢性丙型肝炎患者聚乙二醇干扰素-a2b 和利巴韦林治疗中树突状细胞频率和功能与病毒学复发的关系。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KANTO Tatsuya其他文献

KANTO Tatsuya的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KANTO Tatsuya', 18)}}的其他基金

Development of novel therapy for hepatocellular carcinoma targeting of bone marrow-derived angiogenesis precursor
以骨髓源性血管生成前体为靶点的肝细胞癌新疗法的开发
  • 批准号:
    22590729
  • 财政年份:
    2010
  • 资助金额:
    $ 2.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Developmental research on dendritic cell-based immunotherapy against chronic hepatitis C and hepatocellular carcinoma
基于树突状细胞的慢性丙型肝炎和肝细胞癌免疫治疗的进展研究
  • 批准号:
    19590765
  • 财政年份:
    2007
  • 资助金额:
    $ 2.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

HMGB1-TLR4通路在干燥综合征唾液腺损伤中的作用及机制
  • 批准号:
    81901586
  • 批准年份:
    2019
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目
组蛋白去乙酰化酶HDAC9对树突状细胞功能的调节作用
  • 批准号:
    31900647
  • 批准年份:
    2019
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目
蛋白激酶Stk38对树突状细胞IL-12的产生和Th1型抗结核免疫反应的调节作用
  • 批准号:
    81801570
  • 批准年份:
    2018
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
肠道菌群-TLR5-IL-6在肝癌中的作用及机制研究
  • 批准号:
    81801640
  • 批准年份:
    2018
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
基于TLR9-pDCs-CD4+CXCR3+T研究青蒿鳖甲药对配伍治疗SLE动脉粥样硬化的机制
  • 批准号:
    81803806
  • 批准年份:
    2018
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

C-Type Lectins and Immune Surveillance in ALD
C 型凝集素与 ALD 中的免疫监视
  • 批准号:
    10925432
  • 财政年份:
    2022
  • 资助金额:
    $ 2.56万
  • 项目类别:
C-Type Lectins and Immune Surveillance in ALD
C 型凝集素与 ALD 中的免疫监视
  • 批准号:
    10683563
  • 财政年份:
    2022
  • 资助金额:
    $ 2.56万
  • 项目类别:
C-Type Lectins and Immune Surveillance in ALD
C 型凝集素与 ALD 中的免疫监视
  • 批准号:
    10020883
  • 财政年份:
    2019
  • 资助金额:
    $ 2.56万
  • 项目类别:
MyD88-dependent B cell dysfunction and autoimmunity during chronic liver disease
慢性肝病期间 MyD88 依赖性 B 细胞功能障碍和自身免疫
  • 批准号:
    9886250
  • 财政年份:
    2017
  • 资助金额:
    $ 2.56万
  • 项目类别:
MyD88-dependent B cell dysfunction and autoimmunity during chronic liver disease
慢性肝病期间 MyD88 依赖性 B 细胞功能障碍和自身免疫
  • 批准号:
    9243006
  • 财政年份:
    2017
  • 资助金额:
    $ 2.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了